

# SARS-CoV-2 (2019-nCoV) Nucleocapsid, WT & Ormicron Recognized Recombinant Rabbit mAb

SARS-CoV-2 (2019-nCoV) Nucleocapsid, WT & Ormicron Recognized Recombinant Rabbit mAb

Catalog # AP94733

## Product Information

<b>Application</b>	WB
<b>Host</b>	Rabbit
<b>Clonality</b>	Recombinant
<b>Calculated MW</b>	46 KDa
<b>Physical State</b>	Liquid
<b>Immunogen</b>	Recombinant SARS-CoV-2 Nucleocapsid Protein
<b>Isotype</b>	IgG
<b>Purity</b>	affinity purified by Protein A
<b>Buffer</b>	0.01M TBS (pH7.4) with 1% BSA, 0.02% Proclin300 and 50% Glycerol.
<b>SUBCELLULAR LOCATION</b>	Virion membrane ; Single-pass type I membrane protein ; Host endoplasmic reticulum-Golgi intermediate compartment membrane ; Single-pass type I membrane protein ; Host cell membrane ; Single-pass type I membrane protein ;Note: Accumulates in the endoplasmic reticulum-Golgi intermediate compartment, where it participates in virus particle assembly. Colocalizes with S in the host endoplasmic reticulum-Golgi intermediate compartment. Some S oligomers are transported to the host plasma membrane, where they may mediate cell-cell fusion.
<b>SUBUNIT</b>	Spike glycoprotein: Homotrimer; each monomer consists of a S1 and a S2 subunit (PubMed:32155444, PubMed:32075877). The resulting peplomers protrude from the virus surface as spikes (By similarity). Interacts with the accessory proteins 3a and 7a.Spike protein S1: Binds to human ACE2.
<b>Post-translational modifications</b>	The cytoplasmic Cys-rich domain is palmitoylated. Spike glycoprotein is digested within host endosomes.Specific enzymatic cleavages in vivo yield mature proteins. The precursor is processed into S1 and S2 by host cell furin or another cellular protease to yield the mature S1 and S2 proteins (PubMed:32155444). Additionally, a second cleavage leads to the release of a fusion peptide after viral attachment to host cell receptor (By similarity). The presence of a furin polybasic cleavage site sets SARS-CoV-2 S apart from SARS-CoV S that possesses a monobasic S1/S2 cleavage site processed upon entry of target cells (PubMed:32155444).Highly decorated by heterogeneous N-linked glycans protruding from the trimer surface.
<b>Important Note</b>	This product as supplied is intended for research use only, not for use in human, therapeutic or diagnostic applications.
<b>Background Descriptions</b>	The SARS-CoV-2 spike (S) protein is the target of vaccine design efforts to end the COVID-19 pandemic. Despite a low mutation rate, isolates with the D614G substitution in the S protein appeared early during the pandemic, and are now the dominant form worldwide. Here, we analyze the D614G mutation in the context of a soluble S ectodomain construct.

## Additional Information

### Target/Specificity

The cytoplasmic Cys-rich domain is palmitoylated. Spike glycoprotein is digested within host endosomes. Specific enzymatic cleavages in vivo yield mature proteins. The precursor is processed into S1 and S2 by host cell furin or another cellular protease to yield the mature S1 and S2 proteins (PubMed:32155444). Additionally, a second cleavage leads to the release of a fusion peptide after viral attachment to host cell receptor (By similarity). The presence of a furin polybasic cleavage site sets SARS-CoV-2 S apart from SARS-CoV S that possesses a monobasic S1/S2 cleavage site processed upon entry of target cells (PubMed:32155444). Highly decorated by heterogeneous N-linked glycans protruding from the trimer surface.

### Dilution

WB=1:500-2000

### Format

0.01M TBS(pH7.4) with 1% BSA, 0.09% (W/V) sodium azide and 50% Glycerol


### Storage

Store at -20 °C for one year. Avoid repeated freeze/thaw cycles. When reconstituted in sterile pH 7.4 0.01M PBS or diluent of antibody the antibody is stable for at least two weeks at 2-4 °C.


## Background

This product as supplied is intended for research use only, not for use in human, therapeutic or diagnostic applications.


## Images




Sample: Lane 1: Recombinant SARS-CoV-2 N Protein(Omicron(B.1.1.529) (P13L,E31del,R32del, S33del,R203K,G204R) at 100ng Lane 2: Recombinant SARS-CoV-2 N Protein(Omicron(B.1.1.529) (P13L,E31del,R32del, S33del,R203K,G204R) at 50ng Lane 3: Recombinant SARS-CoV-2 N Protein(Omicron(B.1.1.529) (P13L,E31del,R32del, S33del,R203K,G204R) at 25ng Lane 4: Recombinant SARS-CoV-2 N Protein(Omicron(B.1.1.529) (P13L,E31del,R32del, S33del,R203K,G204R) at 10ng Lane 5: Recombinant SARS-CoV-2 N Protein(Omicron(B.1.1.529) (P13L,E31del,R32del, S33del,R203K,G204R) at 5ng Lane 6: Recombinant SARS-CoV-2 N Protein(WT) at 10ng Primary: Rabbit Anti- SARS-CoV-2 N protein (AP94733) at 1/1000 dilution Secondary: IRDye800CW Goat Anti-Rabbit IgG at 1/20000 dilution Predicted band size:45.3 kD Observed band size:50 kD




Sample: Lane 1:SARS-CoV-2 N Protein (WT) at 10ng Lane 2:SARS-CoV-2 N Protein (Del204 & Del215) at 2ng Lane 3:SARS-CoV-2 N Protein (R203M & D377Y) at 2ng Primary: Rabbit Anti- SARS-CoV-2 N Protein Antibody at 1/1000 dilution Secondary: IRDye800CW Goat Anti-Rabbit IgG at 1/20000 dilution Predicted band size:46kD Observed band size:46kD



Sample: Lane 1:SARS-CoV-2 N Protein (WT) at 10ng Lane 2:SARS-CoV-2 N Protein (Del204 & Del215) at 10ng Lane 3:SARS-CoV-2 N Protein (R203M & D377Y) at 10ng  
Primary: Rabbit Anti- SARS-CoV-2 N Protein Antibody at 1/1000 dilution Secondary: IRDye800CW Goat Anti-Rabbit IgG at 1/20000 dilution Predicted band size:46kD  
Observed band size:46kD



The purity of the protein is greater than 90% as determined by reducing SDS-PAGE.



The purity of the protein is greater than 90% as determined by reducing SDS-PAGE.

Please note: All products are 'FOR RESEARCH USE ONLY. NOT FOR USE IN DIAGNOSTIC OR THERAPEUTIC PROCEDURES'.